Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...

A research team proposes a method to assess cancer patients for their likelihood to either respond to treatment or relapse. Researchers from Iwate Medical University and Tohoku University have ...

Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical risk factors lack ...

In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

Scientists have found that a test to detect circulating tumor DNA can predict lung cancer outcome. Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to ...

The researchers found that within 4 months after blood collection, all 8 participants who scored positively with a multicancer early detection (MCED) test were diagnosed with cancer. HealthDay News — ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...